Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Aucubin has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Iridoid glycosides pass the small intestine largely intact and meet bacterial beta-glucosidase in the colon. The released aglycone is the more absorbable species. That makes the resident microbiota a gate on exposure, which is a plausible reason for the person to person variability seen with this class. This is mechanistic reasoning, not a measured co-administration result.
Inulin fermentation favours Bifidobacterium and related genera, several of which carry broad glycoside hydrolase activity. More of that activity in the colon means more deglycosylation of an iridoid glycoside reaching it. The logic is sound and the direct measurement for aucubin specifically has not been done. Read it as mechanistic rather than clinical.
Aucubin has been described as activating Nrf2 driven antioxidant gene expression in animal and cell work, which raises the enzymes that use glutathione. NAC supplies the rate-limiting cysteine for making glutathione itself. One raises demand-side capacity, the other raises substrate. The combination is coherent on paper and has not been tested together in people.
Quercetin glycosides and iridoid glycosides both rely on intestinal and bacterial glucosidase activity, then on phase II conjugation. At high combined intakes those steps can saturate, which is a competition rather than a boost. The direction is worth stating even though the size is unknown. Not a reason to avoid the pair.
Iridoid glycosides with a hemiacetal are known to degrade under acidic conditions, producing reactive dialdehyde intermediates that polymerise. A high ascorbic acid load in a liquid or effervescent format lowers pH and can drive that. In a dry capsule the concern is minimal. This is a formulation point rather than a physiological one.
Nothing specific on file for Aucubin. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 2 we read for Aucubin. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.